$MEDI to use wearable bio-tech in coming studies $MEDI.N / $KONEF confirms that they will be conducting 2 studies in partnership with Biostrap to use wearable tech to collect biological data from depression and PTSD patients while they receive ketamine treatment.
These studies will be the first of their kind, collecting real-time, advanced health data from 200 patients across their Canadian and American clinics
After the completion of the studies $MEDI will be able to implement an interactive data management tool which will have the ability to analyze, monitor, and visually display key ketamine treatment outcomes.
With this tech clinicians can track patient biometrics, medically validate outcomes, and learn about AI-based depression predictions.
$MEDI dropped 10% out of no wear today meaning that it is trading @ just $0.465/share. Today could be a great opportunity to invest in them on the cheap. MC is $55.87 M.
https://finance.yahoo.com/news/ketamine-one-features-biostrap-part-070000110.html